MHRA approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a treatment for eligible patients with the myeloproliferative neoplasms (MPNs) blood cancers polycythaemia vera (PV) and essential thrombocythaemia (ET)
- First MHRA approval of an interferon alfa as a monotherapy treatment for adults with essential thrombocythaemia (ET)
- First MHRA approval of an interferon alfa as a monotherapy treatment for adults with polycythaemia vera (PV) without any restrictions
Pharmaand GmbH (pharma&) announced today that the Medicines and Healthcare products Regulatory agency (MHRA) has granted marketing authorization for Pegasys® (peginterferon alfa-2a) as a monotherapy treatment for adults with polycythaemia vera (PV) or essential thrombocythaemia (ET).
